BCN HEALTH has presented several communications at the EASL and AASLD congresses evaluating the clinical and economic burden of patients with HDV coinfection and HBV monoinfection in Spain
The EASL congress took place between the 7th and the 10th of May in Amsterdam, while the AASLD congress has taken place between the 7th and the 11th of November in Washington DC.
BCN HEALTH has participated in the EASL and AASLD congresses with several communications that have reported on the clinical and economic burden of patients with HDV coinfection and HBV monoinfection in Spain. The EASL congress took place between the 7th and the 10th of May in Amsterdam, while the AASLD congress has taken place between the 7th and the 11th of November in Washington DC.
The posters have presented information on a retrospective study that included records of patients with HDV coinfection and HBV monoinfection admitted to hospitals in Spain between 2000 and 2019. The objectives of the study were to compare the baseline characteristics of adult patients with HDV/HBV versus hepatitis B monoinfection in Spain. This study reported that the ratio between men and women was similar in the two cohorts. This study concludes that HDV co-infected patients had higher comorbidities and significantly higher liver disease severity than HBV patients. These findings underline the need for early screening and diagnosis, and eventual treatment of HDV to mitigate future disease progression.
Finally, another poster has informed about morbidity and mortality in HDV vs HBV only patients hospitalised in Spain between 2000 and 2019. The results of the study highlight that inpatient length of stay, HCRU, and costs from liver-related morbidities were significantly greater in the 12 months prior to death for patients with HDV vs HBV only. These results further confirm the need for early screening and diagnosis and treatment of HDV to alleviate disease progression.